Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Idiopathic Pulmonary Fibrosis | Research

Waiting time and mortality rate on lung transplant candidates in Japan: a single-center retrospective cohort study

Authors: Takashi Hirama, Miki Akiba, Tatsuaki Watanabe, Yui Watanabe, Hirotsugu Notsuda, Hisashi Oishi, Hiromichi Niikawa, Yoshinori Okada

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

As lung transplantation (LTX) is a valuable treatment procedure for end-stage pulmonary disease, delayed referral to a transplant center should be avoided. We aimed to conduct a single-center analysis of the survival time after listing for LTX and waitlist mortality in each disease category in a Japanese population.

Methods

We included patients listed for LTX at Tohoku University Hospital from January 2007 to December 2020 who were followed up until March 2021. Pulmonary disease was categorized into the Obstructive, Vascular, Suppurative, Fibrosis, and Allogeneic groups. Risk factors for waitlist mortality were assessed using a Cox proportional hazards model. The Kaplan–Meier method was used to model time to death.

Results

We included 269 LTX candidates. Of those, 100, 72, and 97 patients were transplanted, waiting, and dead, respectively. The median time to LTX and time to death were 796 days (interquartile range [IQR] 579–1056) and 323 days (IQR 129–528), respectively. The Fibrosis group showed the highest mortality (50.9%; p < .001), followed by the Allogeneic (35.0%), Suppurative (33.3%), Vascular (32.1%), and Obstructive (13.1%) groups. The Fibrosis group showed a remarkable risk for waitlist mortality (hazard ratio 3.32, 95% CI 2.11–4.85).

Conclusions

In Japan, the waiting time is extremely long and candidates with Fibrosis have high mortality. There is a need to document outcomes based on the underlying disease for listed LTX candidates to help determine the optimal timing for listing patients based on the estimated local waiting time.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mitchell AB, Glanville AR. Lung transplantation: a review of the optimal strategies for referral and patient selection. Ther Adv Respir Dis. 2019;13:1753466619880078.CrossRef Mitchell AB, Glanville AR. Lung transplantation: a review of the optimal strategies for referral and patient selection. Ther Adv Respir Dis. 2019;13:1753466619880078.CrossRef
2.
go back to reference Shweish O, Dronavalli G. Indications for lung transplant referral and listing. J Thorac Dis. 2019;11(Suppl 14):S1708–20.CrossRef Shweish O, Dronavalli G. Indications for lung transplant referral and listing. J Thorac Dis. 2019;11(Suppl 14):S1708–20.CrossRef
3.
go back to reference Valapour M, Lehr CJ, Skeans MA, Smith JM, Miller E, Goff R, et al. OPTN/SRTR 2019 annual data report: lung. Am J Transplant. 2021;21:441–520.CrossRef Valapour M, Lehr CJ, Skeans MA, Smith JM, Miller E, Goff R, et al. OPTN/SRTR 2019 annual data report: lung. Am J Transplant. 2021;21:441–520.CrossRef
4.
go back to reference Egan TM, Edwards LB. Effect of the lung allocation score on lung transplantation in the United States. J Hear Lung Transplant. 2016;35:433–9.CrossRef Egan TM, Edwards LB. Effect of the lung allocation score on lung transplantation in the United States. J Hear Lung Transplant. 2016;35:433–9.CrossRef
5.
go back to reference Mooney JJ, Bhattacharya J, Dhillon GS. Effect of broader geographic sharing of donor lungs on lung transplant waitlist outcomes. J Hear Lung Transplant. 2019;38:136–44.CrossRef Mooney JJ, Bhattacharya J, Dhillon GS. Effect of broader geographic sharing of donor lungs on lung transplant waitlist outcomes. J Hear Lung Transplant. 2019;38:136–44.CrossRef
6.
go back to reference Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRef Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRef
8.
go back to reference Stehlik J, Stevenson LW, Edwards LB, Crespo-Leiro MG, Delgado JF, Dorent R, et al. Organ allocation around the world: insights from the ISHLT international registry for heart and lung transplantation. J Hear Lung Transplant. 2014;33:975–84.CrossRef Stehlik J, Stevenson LW, Edwards LB, Crespo-Leiro MG, Delgado JF, Dorent R, et al. Organ allocation around the world: insights from the ISHLT international registry for heart and lung transplantation. J Hear Lung Transplant. 2014;33:975–84.CrossRef
10.
go back to reference Bennett D, Fossi A, Bargagli E, Refini RM, Pieroni M, Luzzi L, et al. Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: a single-centre experience. Lung. 2015;193:677–81.CrossRef Bennett D, Fossi A, Bargagli E, Refini RM, Pieroni M, Luzzi L, et al. Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: a single-centre experience. Lung. 2015;193:677–81.CrossRef
11.
go back to reference De Oliveira NC, Julliard W, Osaki S, Maloney JD, Cornwell RD, Sonetti DA, et al. Lung transplantation for high-risk patients with idiopathic pulmonary fibrosis Sarcoidosis. Vasc Diffus lung Dis Off J WASOG. 2016;33:235–41. De Oliveira NC, Julliard W, Osaki S, Maloney JD, Cornwell RD, Sonetti DA, et al. Lung transplantation for high-risk patients with idiopathic pulmonary fibrosis Sarcoidosis. Vasc Diffus lung Dis Off J WASOG. 2016;33:235–41.
12.
go back to reference Ikezoe K, Handa T, Tanizawa K, Chen-Yoshikawa TF, Kubo T, Aoyama A, et al. Prognostic factors and outcomes in Japanese lung transplant candidates with interstitial lung disease. PLoS ONE. 2017;12:1–13.CrossRef Ikezoe K, Handa T, Tanizawa K, Chen-Yoshikawa TF, Kubo T, Aoyama A, et al. Prognostic factors and outcomes in Japanese lung transplant candidates with interstitial lung disease. PLoS ONE. 2017;12:1–13.CrossRef
13.
go back to reference Miyahara S, Waseda R, Tokuishi K, Sato T, Iwasaki A, Shiraishi T. Elucidation of prognostic factors and the effect of anti-fibrotic therapy on waitlist mortality in lung transplant candidates with idiopathic interstitial pneumonias. Respir Investig. 2021;59:428–35.CrossRef Miyahara S, Waseda R, Tokuishi K, Sato T, Iwasaki A, Shiraishi T. Elucidation of prognostic factors and the effect of anti-fibrotic therapy on waitlist mortality in lung transplant candidates with idiopathic interstitial pneumonias. Respir Investig. 2021;59:428–35.CrossRef
14.
go back to reference George PM, Patterson CM, Reed AK, Thillai M. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med. 2019;7:271–82.CrossRef George PM, Patterson CM, Reed AK, Thillai M. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med. 2019;7:271–82.CrossRef
15.
go back to reference Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Hear Lung Transplant. 2015;34:1–15.CrossRef Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Hear Lung Transplant. 2015;34:1–15.CrossRef
16.
go back to reference Du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382–9.CrossRef Du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382–9.CrossRef
17.
go back to reference Wille KM, Harrington KF, DeAndrade JA, Vishin S, Oster RA, Kaslow RA. Disparities in lung transplantation before and after introduction of the lung allocation score. J Heart Lung Transplant. 2013;32:684–92.CrossRef Wille KM, Harrington KF, DeAndrade JA, Vishin S, Oster RA, Kaslow RA. Disparities in lung transplantation before and after introduction of the lung allocation score. J Heart Lung Transplant. 2013;32:684–92.CrossRef
18.
go back to reference Yamashiro Y, Shimizu T, Oguchi S, Shioya T, Nagata S, Ohtsuka Y. The estimated incidence of cystic fibrosis in Japan. J Pediatr Gastroenterol Nutr. 1997;24:544–7.CrossRef Yamashiro Y, Shimizu T, Oguchi S, Shioya T, Nagata S, Ohtsuka Y. The estimated incidence of cystic fibrosis in Japan. J Pediatr Gastroenterol Nutr. 1997;24:544–7.CrossRef
20.
go back to reference Chambers DC, Cherikh WS, Harhay MO, Hayes D, Hsich E, Khush KK, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019;38:1042–55.CrossRef Chambers DC, Cherikh WS, Harhay MO, Hayes D, Hsich E, Khush KK, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019;38:1042–55.CrossRef
21.
go back to reference Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant. 2011;46:1283–95.CrossRef Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant. 2011;46:1283–95.CrossRef
22.
go back to reference Greer M, Riise GC, Hansson L, Perch M, Hämmäinen P, Roux A, et al. Dichotomy in pulmonary graft-versus-host disease evident among allogeneic stem-cell transplant recipients undergoing lung transplantation. Eur Respir J. 2016;48:1807–10.CrossRef Greer M, Riise GC, Hansson L, Perch M, Hämmäinen P, Roux A, et al. Dichotomy in pulmonary graft-versus-host disease evident among allogeneic stem-cell transplant recipients undergoing lung transplantation. Eur Respir J. 2016;48:1807–10.CrossRef
23.
go back to reference Glanville AR, Verleden GM, Todd JL, Benden C, Calabrese F, Gottlieb J, et al. Chronic lung allograft dysfunction: definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. J Hear Lung Transplant. 2019;38:483–92.CrossRef Glanville AR, Verleden GM, Todd JL, Benden C, Calabrese F, Gottlieb J, et al. Chronic lung allograft dysfunction: definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. J Hear Lung Transplant. 2019;38:483–92.CrossRef
Metadata
Title
Waiting time and mortality rate on lung transplant candidates in Japan: a single-center retrospective cohort study
Authors
Takashi Hirama
Miki Akiba
Tatsuaki Watanabe
Yui Watanabe
Hirotsugu Notsuda
Hisashi Oishi
Hiromichi Niikawa
Yoshinori Okada
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01760-8

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine